Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Mouridsen

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group StudyM Van Glabbeke, A T van Oosterom, J W Oosterhuis, et al.
British Journal of Cancer|December 23, 1998
High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma groupO S Nielsen, P Dombernowsky, H Mouridsen, et al.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2000
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast groupL Hakamies-Blomqvist, M Luoma, J Sjöström, et al.
Journal of Advanced Nursing|September 1, 2001
Timing of quality of life (QoL) assessments as a source of error in oncological trialsL Hakamies-Blomqvist, M L Luoma, J Sjöström, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2003
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancerM-L Luoma, L Hakamies-Blomqvist, J Sjöström, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 2000
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast GroupJ Sjöström, C Blomqvist, H Mouridsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2011
Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trialB Ejlertsen, J Aldridge, K V Nielsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2009
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trialM Rabaglio, Z Sun, K N Price, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trialG Viale, M M Regan, P Dell'Orto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialL Mauriac, A Keshaviah, M Debled, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group StudyM Van Glabbeke, A T van Oosterom, J W Oosterhuis, et al.
British Journal of Cancer|December 23, 1998
High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma groupO S Nielsen, P Dombernowsky, H Mouridsen, et al.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2000
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast groupL Hakamies-Blomqvist, M Luoma, J Sjöström, et al.
Journal of Advanced Nursing|September 1, 2001
Timing of quality of life (QoL) assessments as a source of error in oncological trialsL Hakamies-Blomqvist, M L Luoma, J Sjöström, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2003
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancerM-L Luoma, L Hakamies-Blomqvist, J Sjöström, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 2000
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast GroupJ Sjöström, C Blomqvist, H Mouridsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2011
Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trialB Ejlertsen, J Aldridge, K V Nielsen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2009
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trialM Rabaglio, Z Sun, K N Price, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trialG Viale, M M Regan, P Dell'Orto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialL Mauriac, A Keshaviah, M Debled, et al.
Pageof 6